4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Antagonism of nerve growth factor-TrkA signaling and the relief of pain.

      Anesthesiology
      Adult, Analgesics, pharmacology, therapeutic use, Animals, Brain-Derived Neurotrophic Factor, physiology, Disease Models, Animal, Humans, Nerve Growth Factors, antagonists & inhibitors, Neuroma, pathology, Nociceptors, drug effects, Pain, drug therapy, Receptor, trkA, Receptors, Nerve Growth Factor, metabolism, Signal Transduction

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Nerve growth factor (NGF) was originally discovered as a neurotrophic factor essential for the survival of sensory and sympathetic neurons during development. However, in the adult NGF has been found to play an important role in nociceptor sensitization after tissue injury. The authors outline mechanisms by which NGF activation of its cognate receptor, tropomyosin-related kinase A receptor, regulates a host of ion channels, receptors, and signaling molecules to enhance acute and chronic pain. The authors also document that peripherally restricted antagonism of NGF-tropomyosin-related kinase A receptor signaling is effective for controlling human pain while appearing to maintain normal nociceptor function. Understanding whether there are any unexpected adverse events and how humans may change their behavior and use of the injured/degenerating tissue after significant pain relief without sedation will be required to fully appreciate the patient populations that may benefit from these therapies targeting NGF.

          Related collections

          Author and article information

          Comments

          Comment on this article